Recent 8-K filings for ALLO

• May 28, 2026, 5:06 PM ET leadership materiality 0.65 neutral item 5.02

  Allogene appoints Zachary Roberts as CEO effective July 1, 2026; David Chang becomes non-employee director

  Zachary Roberts, M.D., Ph.D., currently EVP R&D and CMO, named President and CEO effective July 1, 2026.

• May 13, 2026, 4:03 PM ET earnings materiality 0.65 neutral item 1.01item 1.02item 2.02item 9.01

  Allogene Q1 net loss $42.6M; ALPHA3 interim shows 58% MRD clearance; cash runway extended to Q1 2029

  Terminated exclusive license with Overland; retains ~3% equity; no termination payments.

• April 15, 2026, 7:59 PM ET other material materiality 0.75 neutral item 8.01item 9.01

  Allogene prices $175M public offering of 87.5M shares at $2.00 per share

  Offering of 87,500,000 shares at $2.00/share; gross proceeds ~$175M before discounts and expenses.

• April 13, 2026, 7:59 PM ET other material materiality 0.80 positive item 8.01

  Allogene's cema-cel shows 41.6% MRD clearance advantage in ALPHA3 Phase 2 interim

  58.3% (7/12) of cema-cel patients achieved MRD negativity vs 16.7% (2/12) in observation arm.

• April 13, 2026, 7:59 PM ET other material materiality 0.65 negative item 8.01

  Allogene Therapeutics launches underwritten public offering, suspends ATM sales

  Company announced proposed underwritten public offering of common stock on April 13, 2026.

• March 12, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Allogene Q4 net loss $38.8M; cash runway into Q1 2028; cema-cel ALPHA3 interim April 2026

  Q4 net loss $38.8M ($0.17/share); FY 2025 net loss $190.9M ($0.87/share).

• November 6, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Allogene Therapeutics Reports Q3 2025 Net Loss of $41.4M, Cash of $277.1M

  Q3 2025 net loss $41.4M ($0.19 per share), cash $277.1M, cash runway into 2H 2027.

• October 14, 2025, 7:59 PM ET litigation materiality 0.65 negative item 8.01

  Allogene reports patent infringement lawsuit against licensor Cellectis by Factor Bioscience

  Factor Bioscience filed a complaint in Delaware against Cellectis and AstraZeneca on Sept 26, 2025, alleging TALEN gene-editing patent infringement.

• August 13, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Allogene Q2 net loss $50.9M; highlights ALPHA3 trial progress and ALLO-329 autoimmune initiation

  Net loss of $50.9M ($0.23/share) for Q2 2025; cash and investments $302.6M as of June 30, 2025.

• August 1, 2025, 7:59 PM ET other material materiality 0.90 negative item 8.01

  Allogene drops ALLO-647 after Grade 5 death; pivots to Dagger platform

  Grade 5 hepatic failure from adenovirus attributed to ALLO-647; FC+ALLO-647 arm closed in ALPHA3 study.

• June 23, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07item 9.01

  Allogene shareholders elect three Class I directors, approve say-on-pay, ratify auditor

  Elizabeth Barrett, Arie Belldegrun, and David Chang elected as Class I directors with >131M votes for each.

• May 13, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Allogene Q1 net loss $59.7M; ALPHA3 milestone delayed to 1H 2026; cash runway to 2H 2027

  Net loss $59.7M ($0.28/sh); R&D $50.2M, G&A $15M; cash, equivalents & investments $335.5M.

• March 13, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Allogene reports Q4 net loss $59.9M; cash $373.1M; pipeline milestones 2025-2027

  Q4 net loss $59.9M ($0.28/share); FY net loss $257.6M ($1.32/share); R&D expense $45M Q4.

• February 25, 2025, 6:59 PM ET other material materiality 0.55 neutral item 1.01

  Allogene expands collaboration with Foresight for MRD companion diagnostic; commits $37.3M

  Amended agreement covers MRD assay development as companion diagnostic for cema-cel in EU, UK, Canada, Australia.

• January 29, 2025, 6:59 PM ET leadership materiality 0.55 neutral item 5.02

  Allogene Therapeutics officer Timothy Moore to depart Feb 28, 2025

  Timothy Moore leaving employment on February 28, 2025; departure treated as termination without cause.

• November 13, 2024, 6:59 PM ET other material materiality 0.60 negative item 8.01

  Allogene discontinues enrollment in Phase 1 cema-cel CLL trial due to slow accrual

  Discontinued the Phase 1 cohort in ALPHA2 trial for cema-cel in relapsed/refractory CLL after BTKi/BCL2i therapy.

• November 7, 2024, 6:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Allogene Q3 2024 net loss $66.3M; cash $403.4M; cash runway into 2H 2026

  Net loss of $66.3M ($0.32/share) including $13.4M stock-based comp and $10.7M impairment; R&D $44.7M, G&A $16.3M.

• October 7, 2024, 7:59 PM ET other materiality 0.05 neutral item 5.05item 9.01

  Allogene Therapeutics amends Code of Business Conduct and Ethics

  Updates insider trading policy, antitrust restrictions, and conflicts-of-interest procedures.

• August 7, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Allogene Q2 net loss $66.4M ($0.35/sh); initiated pivotal ALPHA3 trial for cema-cel

  Net loss of $66.4M ($0.35 per share) includes $13.6M stock-based comp and $5.0M impairment.

• June 10, 2024, 7:59 PM ET leadership materiality 0.25 neutral item 5.02item 5.07item 9.01

  Allogene appoints new principal accounting officer; shareholders elect directors and ratify auditor

  Annie Yoshiyama appointed principal accounting officer, replacing Geoffrey Parker; Parker remains CFO.

• May 31, 2024, 7:59 PM ET M&A materiality 0.65 neutral item 1.01

  Allogene restructures JV; ownership diluted to 15.4%, license royalty amended to flat mid-single-digit

  JV acquires Overland US (lead asset OL-101, autologous GPRC5D-BCMA CAR-T for multiple myeloma).

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event earnings

2 positive 4 negative 15 neutral

source · ALLO on sec.gov